
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is poised for success as a clinical-stage biotechnology company with a proprietary Native Complex Platform that has the potential to unlock the full potential of GPCR therapies. With a pipeline of product candidates focused on three therapeutic areas and upcoming clinical data release in the first half of 2026, Septerna is set to make a significant impact in the biotech industry. Additionally, the recent increase in price target to $35 reflects the company's strong financials and optimistic outlook.
Bears say
Septerna is making progress in its preclinical-stage development and has several programs in its pipeline, but has yet to identify a lead candidate for its TSHR NAM program. While the company has a partnership with Novo Nordisk, the financials and prospects seem risky and uncertain, with a conservative estimated price objective of $35 per share. Delays in clinical development and setbacks in trials, as well as potential approval and market penetration issues, pose additional risks for the company's success.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares